ATE342067T1 - Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon - Google Patents

Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon

Info

Publication number
ATE342067T1
ATE342067T1 AT98935852T AT98935852T ATE342067T1 AT E342067 T1 ATE342067 T1 AT E342067T1 AT 98935852 T AT98935852 T AT 98935852T AT 98935852 T AT98935852 T AT 98935852T AT E342067 T1 ATE342067 T1 AT E342067T1
Authority
AT
Austria
Prior art keywords
fusions
proliferative diseases
vascular proliferative
treating vascular
treating
Prior art date
Application number
AT98935852T
Other languages
German (de)
English (en)
Inventor
Gary J Nabel
Elizabeth G Nabel
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE342067T1 publication Critical patent/ATE342067T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT98935852T 1997-07-21 1998-07-21 Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon ATE342067T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/897,333 US6177272B1 (en) 1997-07-21 1997-07-21 Method for treating vascular proliferative diseases with p27 and fusions thereof

Publications (1)

Publication Number Publication Date
ATE342067T1 true ATE342067T1 (de) 2006-11-15

Family

ID=25407780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98935852T ATE342067T1 (de) 1997-07-21 1998-07-21 Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon

Country Status (8)

Country Link
US (2) US6177272B1 (enExample)
EP (1) EP0998307B1 (enExample)
JP (1) JP2001510028A (enExample)
AT (1) ATE342067T1 (enExample)
AU (1) AU8502198A (enExample)
CA (1) CA2295199C (enExample)
DE (1) DE69836139T2 (enExample)
WO (1) WO1999003508A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6413943B1 (en) * 1999-03-01 2002-07-02 Cell Genesys, Inc. Methods and reagents for inhibiting proliferation of smooth muscle cells
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
CA2362995A1 (en) 1999-03-01 2000-09-08 Cell Genesys, Inc. Anti-neoplastic compositions and uses thereof
WO2001021793A1 (fr) 1999-09-22 2001-03-29 Nobuyuki Miyasaka TRAITEMENTS CONTRE LES RHUMATISMES A BASE DE p21?Cip1¿
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
WO2002026139A1 (en) * 2000-09-29 2002-04-04 Cordis Corporation Coated medical devices
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
US20020098998A1 (en) * 2001-01-22 2002-07-25 Marks Andrew R. P27 prevents cellular migration
US20030013638A1 (en) * 2001-01-22 2003-01-16 Marks Andrew R. P27 prevents cellular migration
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
US20030065345A1 (en) * 2001-09-28 2003-04-03 Kevin Weadock Anastomosis devices and methods for treating anastomotic sites
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
WO2006031210A1 (en) * 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
JP2011512408A (ja) * 2008-02-19 2011-04-21 セラドン・コーポレーション 心筋層へのウイルスベクターの取り込みを増大させるための組成物
WO2021005009A1 (en) 2019-07-05 2021-01-14 Iomx Therapeutics Ag Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
US20240010720A1 (en) 2020-07-06 2024-01-11 Iomx Therapeutics Ag Antibodies binding igv of igsf11 (vsig3) and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6242575B1 (en) 1994-01-07 2001-06-05 Fred Hutchinson Institute For Cancer Research Antibodies for detecting p27 protein
US6316208B1 (en) 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US6355774B1 (en) 1994-01-07 2002-03-12 Fred Hutchinson Cancer Research Center Isolated p27 protein
US5688665A (en) 1994-01-07 1997-11-18 Fred Hutchinson Cancer Research Center Isolated nucleic acid molecules encoding the p27 KIP-1 protein
AU2770695A (en) 1994-07-15 1996-02-16 Fred Hutchinson Cancer Research Center Isolated p27 protein and methods for its production and use
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors
US5962424A (en) * 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US6541197B2 (en) * 1996-01-22 2003-04-01 Human Gene Therapy Research Institute Vehicles for stable transfer of green fluorescent protein gene and methods of use for same
US5672508A (en) * 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
WO1998021350A1 (en) * 1996-11-13 1998-05-22 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement

Also Published As

Publication number Publication date
DE69836139D1 (de) 2006-11-23
US6884431B1 (en) 2005-04-26
DE69836139T2 (de) 2007-08-16
WO1999003508A9 (en) 1999-05-14
EP0998307A2 (en) 2000-05-10
WO1999003508A3 (en) 1999-04-08
CA2295199C (en) 2007-07-03
AU8502198A (en) 1999-02-10
JP2001510028A (ja) 2001-07-31
WO1999003508A2 (en) 1999-01-28
EP0998307B1 (en) 2006-10-11
US6177272B1 (en) 2001-01-23
CA2295199A1 (en) 1999-01-28

Similar Documents

Publication Publication Date Title
ATE342067T1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
DE60043957D1 (de) Verfahren zur Behandlung von Entzündungen
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE69609868D1 (de) Neue steroidester zur behandlung von hauterkrankungen
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69942365D1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
ATE221377T1 (de) Verfahren zur reduzierung der körperfettanteils bei tieren mit der verabreichungvon konjugiergter linolsäure
DE59711321D1 (de) Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69631656D1 (de) Debromhymenialdisin und verwandte verbindungen zur behandlung von osteoarthritis
DE69929787D1 (de) Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69512760D1 (de) Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE59508509D1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties